Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of Zevalin-based reduced-intensity conditioning before allogeneic hematopoietic stem cell transplantation in relapsed chemosensitive aggressive CD20-positive B-cell lymphoma
2007-003821-25Phase 2Active
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Aug 2007
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan in mature B-cell lymphoma and diffuse large B-cell lymphoma (DLBCL), sponsored by Centre Hospitalier Universitaire de Bordeaux. Primary endpoint: Early toxicity. Started Aug 2007; status: active.
02
Drugs
ibritumomab tiuxetan
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2007-003821-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003821-25.